Lee D. Cranmer

9.9k total citations
127 papers, 3.3k citations indexed

About

Lee D. Cranmer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lee D. Cranmer has authored 127 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Lee D. Cranmer's work include Sarcoma Diagnosis and Treatment (44 papers), Vascular Tumors and Angiosarcomas (28 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Lee D. Cranmer is often cited by papers focused on Sarcoma Diagnosis and Treatment (44 papers), Vascular Tumors and Angiosarcomas (28 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Lee D. Cranmer collaborates with scholars based in United States, United Kingdom and France. Lee D. Cranmer's co-authors include Evan M. Hersh, Deborah H. Spector, Christopher S. Morello, Katrina T. Trevor, Sherif S. Morgan, Seth M. Pollack, Igor Puzanov, Wolfram E. Samlowski, Elizabeth T. Loggers and Kristen N. Ganjoo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Lee D. Cranmer

123 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lee D. Cranmer United States	30	1.9k	1.1k	869	822	457	127	3.3k
Brian A. Van Tine United States	31	1.7k 0.9×	1.3k 1.3×	1.6k 1.8×	399 0.5×	337 0.7×	141	3.8k
Alshad S. Lalani United States	34	1.3k 0.7×	1.1k 1.1×	540 0.6×	795 1.0×	763 1.7×	74	3.1k
Michal Lotem Israel	29	3.4k 1.8×	1.9k 1.8×	555 0.6×	1.8k 2.1×	286 0.6×	106	4.9k
Changyu Wang China	24	3.1k 1.6×	1.1k 1.0×	845 1.0×	1.9k 2.4×	258 0.6×	79	4.9k
Venu G. Pillarisetty United States	34	2.3k 1.2×	709 0.7×	407 0.5×	1.9k 2.3×	335 0.7×	84	4.1k
Lorena Landuzzi Italy	37	1.6k 0.8×	2.0k 1.9×	1.0k 1.2×	1.5k 1.8×	226 0.5×	131	4.2k
Xavier Sastre France	33	2.0k 1.0×	822 0.8×	1.5k 1.7×	618 0.8×	237 0.5×	77	4.2k
Gal Markel Israel	41	2.5k 1.3×	1.5k 1.5×	354 0.4×	3.0k 3.6×	509 1.1×	126	5.8k
Jason Konner United States	31	1.8k 0.9×	889 0.8×	525 0.6×	910 1.1×	317 0.7×	122	4.0k
Paul B. Robbins United States	30	1.7k 0.9×	1.0k 1.0×	758 0.9×	798 1.0×	218 0.5×	79	3.1k

Countries citing papers authored by Lee D. Cranmer

Since Specialization

Citations

This map shows the geographic impact of Lee D. Cranmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee D. Cranmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee D. Cranmer more than expected).

Fields of papers citing papers by Lee D. Cranmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee D. Cranmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee D. Cranmer. The network helps show where Lee D. Cranmer may publish in the future.

Co-authorship network of co-authors of Lee D. Cranmer

This figure shows the co-authorship network connecting the top 25 collaborators of Lee D. Cranmer. A scholar is included among the top collaborators of Lee D. Cranmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee D. Cranmer. Lee D. Cranmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagner, Michael J., Erica Pimenta, Elizabeth T. Loggers, et al.. (2025). Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. JCO Precision Oncology. 9(9). e2400592–e2400592.

Cranmer, Lee D., Eric Q. Konnick, Angela Jacobson, et al.. (2024). Combined Germline and Mosaic SDHA Mutation Is Associated With a Multicancer Syndrome Including Neuroblastoma, Renal Cancer, and Multifocal GI Tumor. JCO Precision Oncology. 8(8). e2300455–e2300455.

Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, et al.. (2024). Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 42(13). 1472–1476. 16 indexed citations

Banerji, Udai, William D. Tap, Natalie Cook, et al.. (2024). 646P A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. Annals of Oncology. 35. S511–S511. 1 indexed citations

Alexiev, Borislav A., Eleanor Y. Chen, Brett Schroeder, et al.. (2024). B7-H3 is widely expressed in soft tissue sarcomas. BMC Cancer. 24(1). 1336–1336. 2 indexed citations

Lee, Elizabeth, Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300). Gynecologic Oncology. 176. S185–S185. 1 indexed citations

Cranmer, Lee D., Karla V. Ballman, Elizabeth T. Loggers, et al.. (2023). Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). Clinical Cancer Research. 29(6). 1068–1076. 1 indexed citations

Higgins, Michael S., et al.. (2023). Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Cancer Reports. 6(3). e1792–e1792. 9 indexed citations

Milton, Denái R., William H. Sharfman, Bret Taback, et al.. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology. 10(1). 1984059–1984059. 5 indexed citations

10.

Schroeder, Brett, Bonnie LaFleur, Rachel Gittelman, et al.. (2021). CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. Journal for ImmunoTherapy of Cancer. 9(8). e002812–e002812. 25 indexed citations

11.

Watts, George S., James E. Thornton, Ken Youens‐Clark, et al.. (2019). Identification and quantitation of clinically relevant microbes in patient samples: Comparison of three k-mer based classifiers for speed, accuracy, and sensitivity. PLoS Computational Biology. 15(11). e1006863–e1006863. 17 indexed citations

12.

Kohli, Karan, Yao Lu, Qianchuan He, et al.. (2019). Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunology Research. 7(8). 1237–1243. 101 indexed citations

13.

Clark, Joseph I., Jatinder Singh, Marc S. Ernstoff, et al.. (2018). A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Journal for ImmunoTherapy of Cancer. 6(1). 76–76. 13 indexed citations

14.

Chawla, Sant P., Lee D. Cranmer, Brian A. Van Tine, et al.. (2014). Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. Journal of Clinical Oncology. 32(29). 3299–3306. 122 indexed citations

15.

Thajudeen, Bijin, Machaiah Madhrira, Erika Bracamonte, & Lee D. Cranmer. (2013). Ipilimumab Granulomatous Interstitial Nephritis. American Journal of Therapeutics. 22(3). e84–e87. 60 indexed citations

16.

Cruz‐Muñoz, William, María Jaramillo, Shan Man, et al.. (2012). Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma. Cancer Research. 72(19). 4909–4919. 49 indexed citations

17.

Chalasani, Pavani, Mikhail Shtivelband, & Lee D. Cranmer. (2009). Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.. PubMed. 7(7). 473–5. 2 indexed citations

18.

Vogelzang, Nicholas J., Lee D. Cranmer, Marc S. Ernstoff, et al.. (2009). Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies. Cancer Research. 69. 724–724. 1 indexed citations

19.

Alexandrescu, Doru T, Karl D. Lewis, Wolfram E. Samlowski, et al.. (2007). A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.. Molecular Cancer Therapeutics. 6. 4 indexed citations

20.

Cranmer, Lee D., et al.. (2005). Rodent models of brain metastasis in melanoma. Melanoma Research. 15(5). 325–356. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact